Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)

NCT02936037 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

642

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision for business purposes

Conditions

Multiple Sclerosis

Interventions

DRUG: MD1003 100mg capsule
DRUG: PLACEBO

Sponsor

MedDay Pharmaceuticals SA